CONTENIDO

  • Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals

    Luis M Molinos-Albert, Jorge Carrillo, Marta Curriu, Maria L Rodriguez de la Concepción, Silvia Marfil, Elisabet García, Bonaventura Clotet and Julià Blanco.

    Retrovirology 2014, 11:44 doi:10.1186/1742-4690-11-44

  • Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing

    Christian Pou1,2,a, Marc Noguera-Julian1,2,3,a, Susana Pérez-Álvarez1,2, Federico García4, Rafael Delgado5, David Dalmau6,7, Miguel Álvarez-Tejado8, Dimitri Gonzalez9,10, Chalom Sayada9,10, Natalia Chueca4, Federico Pulido5, Laura Ibáñez6, Cristina Rodríguez1,2, Maria Casadellà1,2, José R. Santos2,11, Lidia Ruiz1,2, Bonaventura Clotet1,2,3,11, and Roger Paredes1,2,3,11

    1IrsiCaixa AIDS Research Institute - HIVACAT, Hospital Universitari Germans Trias i Pujol, Badalona 2Universitat Autònoma de Barcelona, Cerdanyola del Vallès 3Universitat de Vic-Universitat Central de Catalunya, Vic 4Microbiology and Molecular Biology Department, Hospital Universitario San Cecilio, Granada 5Laboratory of Molecular Microbiology, Instituto de Investigación Biomedica Hospital 12 de Octubre (i + 12), Madrid 6HIV/AIDS Department, Hospital Universitari MútuaTerrassa 7Universitat de Barcelona, Terrassa 8Roche Diagnostics, SL, Sant Cugat del Vallès 9ABL SA, Barcelona, Spain 10ABL SA, Luxembourg, Luxembourg 11HIV Unit, Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain

    Christian Pou, et al. Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing. Clinical Infectious Diseases. 29 May 2014

  • Zinc-finger endonuclease targeting PSIP-1 inhibits HIV-1 integration

    Badia R, Pauls E, Riveira-Munoz E, Clotet B, Esté JA, Ballana E

     

    See authors' affiliations

    Badia R, Pauls E, Riveira-Munoz E, Clotet B, Esté JA, Ballana E. Antimicrob Agents Chemother. 2014 Aug;58(8):4318-4327

  • Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression

    Dalmau J, Rotger M, Erkizia I, Rauch A, Reche P, Pino M, Esteve A, Palou E, Brander C, Paredes R, Phung P, Clotet B, Telenti A, Martinez-Picado J, Prado JG; The CoRP Study Group.

    Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. Dalmau J, Rotger M, Erkizia I, Rauch A, Reche P, Pino M, Esteve A, Palou E, Brander C, Paredes R, Phung P, Clotet B, Telenti A, Martinez-Picado J, Prado JG; The CoRP Study Group. AIDS. 2014 Apr 12. [Epub ahead of print] PMID: 24732774

  • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

    Dr Bonaventura Clotet MD, Prof Judith Feinberg MD, Prof Jan van Lunzen MD, Marie-Aude Khuong-Josses MD, Andrea Antinori MD, Irina Dumitru MD, Prof Vadim Pokrovskiy MD, Jan Fehr MD, Roberto Ortiz MD, Prof Michael Saag MD, Julia Harris MA, Clare Brennan DPT, Tamio Fujiwara PhD, Sherene Min MD, on behalf of the ING114915 Study Team, Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. The Lancet (2014) doi:10.1016/S0140-6736(14)60084-2

     

    Read abstract online in The Lancet

    The Lancet (2014) doi:10.1016/S0140-6736(14)60084-2